Clearmind Medicine has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder patients using the company’s proprietary MEAI-based CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trial, at the Yale School of Medicine’s Department of Psychiatry and the Johns Hopkins University School of Medicine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CMND:
- Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
- Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
- Rising High: Exclusive talk with multi-state operator C3 Industries
- Rising High: Exclusive talk with vape tech developer Ispire Technology
- Clearmind Medicine submits three additional international patent applications